FDA's Longstanding Regulatory Drug Policy Chief Jane Axelrad To Retire

FDA's drug regulatory policy chief Jane Axelrad will step down the end of April after serving at the agency for 25 years and playing an integral role in FDA reform and user fee negotiations. She recently served as the lead on the agency's compounding efforts following the 2012 fungal meningitis outbreak, including heading up talks leading up to enactment of the compounding provisions in the Drug Quality and Security Act. Axelrad, who is the Center for Drug Evaluation and Research's...